...
首页> 外文期刊>Stem cells translational medicine. >Large‐Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34+ Cells
【24h】

Large‐Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34+ Cells

机译:从脐带血CD34 +细胞大规模体外产生人红细胞

获取原文
           

摘要

The ex vivo generation of human red blood cells on a large scale from hematopoietic stem and progenitor cells has been considered as a potential method to overcome blood supply shortages. Here, we report that functional human erythrocytes can be efficiently produced from cord blood (CB) CD34+ cells using a bottle turning device culture system. Safety and efficiency studies were performed in murine and nonhuman primate (NHP) models. With the selected optimized culture conditions, one human CB CD34+ cell could be induced ex vivo to produce up to 200 million erythrocytes with a purity of 90.1%?±?6.2% and 50%?±?5.7% (mean?±?SD) for CD235a+ cells and enucleated cells, respectively. The yield of erythrocytes from one CB unit (5 million CD34+ cells) could be, in theory, equivalent to 500 blood transfusion units in clinical application. Moreover, induced human erythrocytes had normal hemoglobin content and could continue to undergo terminal maturation in the murine xenotransplantation model. In NHP model, xenotransplantation of induced human erythrocytes enhanced hematological recovery and ameliorated the hypoxia situation in the primates with hemorrhagic anemia. These findings suggested that the ex vivo‐generated erythrocytes could be an alternative blood source for traditional transfusion products in the clinic. S tem C ells T ranslational M edicine 2017;6:1698–1709
机译:从造血干细胞和祖细胞大规模离体产生人红细胞已被认为是克服血液供应短缺的一种潜在方法。在这里,我们报告说,使用转瓶器培养系统可以从脐带血(CB)CD34 + 细胞有效地生产功能性人类红细胞。在鼠类和非人类灵长类动物(NHP)模型中进行了安全性和效率研究。通过选择最佳的培养条件,可以离体诱导一个人CB CD34 + 细胞产生多达2亿个红细胞,纯度为90.1%±6.2%和50%±5.7。 CD235a + 细胞和去核细胞的百分比(平均值±SD)。从理论上讲,一个CB单位(500万CD34 + 细胞)的红细胞产量在临床上可以相当于500个输血单位。而且,诱导的人红细胞具有正常的血红蛋白含量,并且在鼠异种移植模型中可以继续经历终末成熟。在NHP模型中,诱导的人类红细胞的异种移植可增强血液贫血的灵长类动物的血液学恢复并改善缺氧状况。这些发现表明,离体产生的红细胞可能是临床上传统输血产品的替代血液来源。 STEM STEEL跨国翻译医学杂志2017; 6:1698–1709

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号